ABSTRACT The lung function response to three doses of salbutamol 0 075 mg/kg given at 10 minute intervals by gastric tube was studied in 31 infants aged 2-22 months with bronchopulmonary disease (eight after the respiratory distress syndrome, 15 with wheezy bronchitis, and eight with cystic fibrosis). Lung function was measured by whole body plethysmography. Seven of 31 infants had normal lung function and 10 ofthe remaining 24 had an increase in thoracic gas volume (TGV), lO an increase in airway resistance (Raw), and four an increase in both the TGV and Raw. The response of TGV and Raw to salbutamol was analysed by circular statistics, enabling analysis of coupled, directional data. Thirty minutes after administration of the first dose of salbutamol there was a reduction in TGV or Raw in 21 ofthe 24 infants, 11 showing a decrease in TGV ("volume responder") and 10 a fall in Raw ("flow responder"). These results indicate that in most infants with bronchopulmonary disease an improvement in lung function can be documented after systemic administration of beta agonists if both TGV and Raw are measured.
Introduction
There is controversy about the role ofbronchodilators in infants under the age of 18 months with bronchopulmonary disease.'-2 Several studies have reported no benefit'" or even a paradoxical deterioration78 after beta agonists, though some infants have responded favourably"'2 and clinical observations appear to support these findings. Several technical factors could be responsible for the failure to detect a response to beta agonists in infants. In most studies the beta agonist was inhaled from a conventional jet type nebuliser and the first question is whether the drug reached its site of action. Wheezy infants commonly have upper airway obstruction and this may impede penetration of the aerosol, especially during test procedures in which the infant is asleep. A (153% (95%) pred). The range of values was wide, however, and the differences between groups were not statistically significant. The scatter of TGV, Raw, and sGaw values within the three diagnostic groups was similar, so the data from the three groups were evaluated together. The younger the infant was independent of the diagnostic group, the higher the TGV. Figure 2 shows individual changes in TGV (x axis) and Raw (y axis) after salbutamol. The patients in whom both TGV and Raw were increased (broken lines) can be distinguished from those with an increase in TGV alone (right lower quadrant) and from those with an increase in Raw alone Qeft upper quadrant). Each segment represents the vectoral changes in TGV and Raw over five minutes.
The angles of the changes were plotted on a unit circle (radius = 1) by means ofcircular statistics2"' to obtain a graphical analogue of a histogram (fig 3) , the origin of each vector (values before drug administration) and the magnitude of change after salbutamol being disregarded. The components and polar The repartitioning of patients into non-responders, volume responders, and flow responders within the three functional groups in relation to time and cumulative dose of salbutamol is summarised in table 4. Thirty minutes after salbutamol only three infants were categorised as "non-responders." Eight of the 10 infants with increased TGV were "volume responders" and two non-responders. Nine of the 10 with increased Raw were "flow responders" and one was a non-responder. In the four infants with an increase in TGV and Raw three were "volume responders" and one a "flow responder." Figure 4 presents the dose-time response course after salbutamol represented by the mean vectors and angle distribution within the three functional groups. The mean vectors have turned counter clockwise to achieve a preferred direction towards the centre of values predicted for both TGV and Raw. Hyperinflated infants showed a predominant "volume response," whereas infants with bronchial obstruction showed a predominant "flow response."
Discussion
The resistance of an airway bears an inverse fourth power relationship to its diameter.25 A progressively greater change in resistance is therefore expected for a given change in smooth muscle length (and hence inspiratory lung volume) as an airway narrows. This Kraemer, Birrer, Schoni implies that the bronchodilator response to beta agonists must be measured in infants by methods that evaluate changes in airway function in relation to changes in static lung volume, as we have already shown in older asthmatic children. '8 The infant whole body plethysmograph allows a static lung volume and airway resistance to be measured. Specific patterns for each disease group were expected. The pattern of the initial lung function disorder was, however, linked more with the severity of the disease and the age of the infant than with the clinical picture (respiratory distress syndrome, wheezy bronchitis, cystic fibrosis). A response to the systemic beta agonist was seen in 21 of 24 infants with bronchopulmonary disease. Of the responders, 11 of the 21 infants showed a decrease in end expiratory resting level (volume responders) and 10 a decrease in Raw (flow responders). Technical aspects The measurement of TGV by plethysmography depends critically on the accuracy with which mouth pressure reflects mean alveolar pressure during respiratory efforts against a closed shutter, and on the precision with which plethysmograph chamber pressure reflects change in alveolar volume under these dynamic conditions. Several studies in adults with airway obstruction have found that TGV may be overestimated because changes in mouth pressure underestimate changes in mean alveolar pressure during respiratory efforts against an occlusion.26 " Plethysmographic measurements in infants have recently been questioned.2" In our study TGV in one infant who had had bronchitis was as high as 445% pred; severe hyperinflation was noted on the chest radiograph. In contrast, Godfrey et aP' found that more than half of the infants studied with recurrent wheeze after bronchiolitis had low values for TGV. In their study the administration of salbutamol to 21 infants resulted in a small rise in TGV (from 78% to 83% pred), whereas in our study TGV decreased in the 15 wheezy infants from 174% to 131% predicted. These discrepancies are presumably due to differences in the techniques used to measure lung volume. In contrast to our technique and that used by Stocks' in the study from which the normal values were taken, measurement of forced flow-volume curves was carried out in the study by Godfrey with the infants in a double walled squeeze jacket covering the child's thorax and abdomen in the infant plethysmograph. Although In all three studies PEFV was measured. The conclusion from these somewhat contradictory findings was that salbutamol has no effect when there is chronic airway narrowing, but has a protective effect when the infant is exposed to an irritant trigger. We believe, however, that technical problems may explain these conflicting results. It was assumed in these studies that maximum flow at functional residual capacity before and after salbutamol was measured at the same end expiratory resting level, an assumption that is unproved as FRC and TGV were not measured. The absence of a bronchodilator response may be due to the fact that they studied severely ill patients, in whom other factors may have been contributing. Using the same technique, Tepper' found a response to beta agonists in 10 healthy male infants after methacholine challenge. FRC was not measured, but it was assumed to have been within the normal range as the subjects were healthy.
In 50 infants with wheezy bronchitis'0 15 showed an increase in specific conductance (calculated by dividing oscillatory conductance by TGV). Responders could not be differentiated from non-responders by family history or laboratory evidence of atopy. The results, contradicting those ofsome previous studies,' 3 were thought to be explained by change in lung volume that had masked an effect of treatment on conductance. '1 These observations in general support our findings that infants with persistent signs of bronchopulmonary disease respond to bronchodilators, if both changes in TGV and airway function are taken into account. The improvement in TGV may be due to improvement of flow by bronchodilatation, with a consequent decrease in end expiratory resting level. Decrease in lung volume will itself narrow the airways and airway resistance may not fall unless the diameter of the airway has changed substantially.
